The Effect of Colistin Inhalation on Ventilator Associated Pneumonia
NCT ID: NCT03622450
Last Updated: 2018-08-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
40 participants
INTERVENTIONAL
2016-01-02
2018-01-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aerosolized Colistin to Mechanical Ventilated Patients With Pneumonia
NCT04633317
Empiric Antibiotic Therapy for Ventilator-acquired Pneumonia With Gram-negative Bacilli in Intensive Care
NCT02127528
Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia
NCT02478710
Reduction of Bacterial Resistance With Inhaled Antibiotics in the Intensive Care Unit
NCT01878643
Open Suction Circuit Flushing With Chlorhexidine Decreases Ventilator-Associated Pneumonia: A Quasi-experimental Study
NCT05206721
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Medication arm
Colistin to be given as 2 millions three times daily in the inhalation form from 5 to 7 days in addition to another antipseudomonal antibiotic according to infectious disease society of antimicrobials (IDSA) guidelines from day 1 of incidence of ventilator associated pneumonia
Colistin
Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
Control arm
Patients receive antipseudomonal antibiotics IV as carbapenem and quinolone or aminoglycoside according to IDSA guidelines from day 1 of incidence of Ventilator associated pneumonia carbapenem as 1g three times daily + tavanic 750mg once daily or ciprofloxacin 500mg twice daily or aminoglycoside according to renal function
Carbapenem + Aminoglycoside/ Quinolone
Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Colistin
Polymyxins are bactericidal drugs that bind to lipopolysaccharides (LPS) and phospholipids in the outer cell membrane of gram-negative bacteria.
Carbapenem + Aminoglycoside/ Quinolone
Dual antipseudomonal given as IV for ventilator associated pneumonia for patients with Multi-drug resistant bacteria risk factors
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Patients presenting with signs of infection 48 hours of intubation
Exclusion Criteria
Cystic fibrosis Known allergy to polymyxin. Patients presenting with chest infection or signs of infection before intubation.
Patients with creatinine clearance less than 30ml/min.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Nourhan Hassan Osama Thuraya Mohamed
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nourhan Hassan Osama Thuraya Mohamed
Clinical pharmacist
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Colistin inhalation form
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.